The new joint venture company – Jilin Pfizer Guoyuan Animal Health – will initially be responsible to develop vaccines to protect the health of swine.
Jilin Guoyuan Animal Health GM Hua Wu said the new joint venture begins operations from a position of strength.
"Pfizer complements Guoyuan with its R&D, manufacturing, regulatory and operational expertise, its founding leadership in the International Veterinary Collaboration for China, a Veterinary Alliance, as well as its growing field force and customer base in China," Wu said.
The joint venture is subject to approval by government authorities in China.